Table 1. Patient and tumor characteristics (n = 125).
| Characteristics | |||
|---|---|---|---|
| Age (years) | 58 | (33–83) | |
| Sex | |||
| Male | 85 | (68) | |
| Female | 40 | (32) | |
| Type of surgery | |||
| SPS | 116 | (93) | |
| APR | 9 | (7) | |
| Performance status | |||
| 0–1 | 123 | (98) | |
| 2 | 2 | (2) | |
| Pre-NCRT CEA level (ng/mL) | 3.0 | (0.5–105.0) | |
| ≤5 | 84 | (67) | |
| >5 | 41 | (33) | |
| Post-NCRT CEA level (ng/mL) | 1.9 | (0.5–27.7) | |
| ≤5 | 114 | (91) | |
| >5 | 11 | (9) | |
| cT stage | |||
| 2 | 9 | (7) | |
| 3 | 109 | (87) | |
| 4 | 7 | (6) | |
| cN stage | |||
| 0 | 15 | (12) | |
| 1 | 78 | (62) | |
| 2 | 32 | (26) | |
| ypT stage | |||
| 0 | 2 | (2) | |
| 1 | 4 | (3) | |
| 2 | 17 | (14) | |
| 3 | 102 | (82) | |
| ypN stage | |||
| 1 | 97 | (78) | |
| 2 | 28 | (22) | |
| No. of examined LNs | 17 | (1–49) | |
| No. of metastatic LNs | 2 | (1–17) | |
| 1 | 56 | (45) | |
| 2–3 | 41 | (33) | |
| ≥4 | 28 | (22) | |
| LNR | 0.143 | (0.02–1) | |
| CRM | |||
| Negative | 103 | (82) | |
| Positive | 22 | (18) | |
| TRG | |||
| 0 | 5 | (4) | |
| 1 | 38 | (30) | |
| 2 | 61 | (49) | |
| 3 | 19 | (15) | |
| 4 | 2 | (2) | |
| Histologic grade | |||
| WD & MD | 115 | (92) | |
| PD & mucinous | 10 | (8) | |
| Angiolymphatic invasion | |||
| Negative | 94 | (75) | |
| Positive | 31 | (25) | |
| Venous invasion | |||
| Negative | 108 | (86) | |
| Positive | 17 | (14) | |
| Perineural invasion | |||
| Negative | 91 | (73) | |
| Positive | 34 | (27) | |
Values are presented as median (range) or number (%).
SPS, sphincter preserving surgery; APR, abdominoperineal resection; NCRT, neoadjuvant chemoradiotherapy; CEA, carcinoembryonic antigen; LN, lymph node; LNR, lymph node ratio; CRM, circumferential resection margin; TRG, tumor regression grade; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated.